1 |
Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, Zarrabi A, Goldman A, Ashrafizadeh M, Orive G. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today 2021:S1359-6446(21)00428-1. [PMID: 34624510 DOI: 10.1016/j.drudis.2021.09.020] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
2 |
Ashrafizadeh M, Delfi M, Hashemi F, Zabolian A, Saleki H, Bagherian M, Azami N, Farahani MV, Sharifzadeh SO, Hamzehlou S, Hushmandi K, Makvandi P, Zarrabi A, Hamblin MR, Varma RS. Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy. Carbohydr Polym 2021;260:117809. [PMID: 33712155 DOI: 10.1016/j.carbpol.2021.117809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
|
3 |
Tong X, Ga L, Ai J, Wang Y. Progress in cancer drug delivery based on AS1411 oriented nanomaterials. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01240-z] [Reference Citation Analysis]
|